NCT06182969View on ClinicalTrials.gov

A Study of APG-2575 in Patients with Mild-to-moderate Systemic Lupus Erythematosus.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 9, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
SLE
Interventions
DRUG

APG-2575

Take orally once daily (QD) for 12 weeks.

OTHER

Placebo

Take orally once daily (QD) for 12 weeks.

Trial Locations (1)

200127

RECRUITING

Renji Hospital Shanghai Jiaotong University School of Medical, Shanghai

Sponsors
All Listed Sponsors
collaborator

Suzhou Yasheng Pharmaceutical Co., Ltd.

INDUSTRY

lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT06182969 - A Study of APG-2575 in Patients with Mild-to-moderate Systemic Lupus Erythematosus. | Biotech Hunter | Biotech Hunter